What the Pre-Authorization Letter Generator actually produces

[Date] Utilization Review Department BlueCross BlueShield of Illinois [Address] RE: Pre-Authorization Request for Outpatient Mental Health Treatment Patient: [Name] Member ID: [Member ID] Group ID: BCB-774920 Date of Birth: [DOB] Provider: [Clinician Name, License] Facility: [Practice Name] Dear Utilization Review Specialist, I am writing to request pre-authorization for 16 additional individual outpatient psychotherapy sessions (60 minutes each, 1 session per week over 4 months) for my patient listed above. CLINICAL PRESENTATION AND DIAGNOSIS: The patient presents with Major Depressive Disorder, recurrent, moderate (F33.1) and Generalized Anxiety Disorder (F41.1). At intake, the patient completed the PHQ-9 (Patient Health Questionnaire-9), scoring 17, indicating moderate-to-severe depressive symptoms. The GAD-7 (Generalized Anxiety Disorder-7) score was 14, indicating moderate anxiety symptomatology. The patient reports persistent depressive episodes with chronic worry, sleep disruption (3–4 hours per night), difficulty concentrating, social withdrawal, and significant occupational impairment. FUNCTIONAL IMPAIRMENTS: The patient's occupational functioning is substantially compromised: inconsistent work attendance, decreased productivity, difficulty managing job responsibilities, and reported fear of job loss. Sleep disturbance significantly impacts daytime functioning and mood regulation. The patient reports social isolation and withdrawal from previously valued relationships. These functional limitations meet criteria for medical necessity for structured mental health treatment. PHARMACOTHERAPY AND JUSTIFICATION FOR PSYCHOTHERAPY: The patient is currently managed on sertraline 100 mg daily, prescribed by her primary care physician. While the patient has shown partial response to pharmacotherapy alone, depressive and anxiety symptoms remain moderate in severity, and the patient continues to exhibit significant functional impairment and risk of further deterioration. The combination of pharmacotherapy with evidence-based psychotherapy is the standard of care for moderate-to-severe depression and anxiety and significantly improves treatment outcomes and reduces relapse risk compared to medication alone. TREATMENT MODALITY AND EVIDENCE BASE: Cognitive Behavioral Therapy (CBT) is specifically requested. CBT is an evidence-based, first-line psychotherapy for both Major Depressive Disorder and Generalized Anxiety Disorder, with strong empirical support from randomized controlled trials and meta-analyses demonstrating efficacy comparable to or superior to pharmacotherapy alone for moderate depression. CBT is manualized, time-limited, and measurable, making it an efficient use of behavioral health resources. JUSTIFICATION FOR REQUESTED NUMBER OF SESSIONS: 16 sessions over 4 months (1 per week) represents a standard course of outpatient CBT for moderate depression. The typical CBT treatment protocol involves: (1) initial assessment and psychoeducation (2 sessions); (2) behavioral activation and behavioral tracking (3–4 sessions); (3) cognitive restructuring and thought work (5–6 sessions); (4) relapse prevention and termination planning (3–4 sessions). Terminating treatment prematurely (fewer than 12–16 sessions) significantly increases relapse risk and risks clinical deterioration requiring higher levels of care (intensive outpatient, partial hospitalization, or inpatient psychiatric hospitalization). PROGNOSIS AND RISK OF UNTREATED DETERIORATION: Without continued structured psychotherapy, the patient faces high risk of: worsening depressive symptoms, escalating anxiety, continued occupational dysfunction and potential job loss, increased isolation, suicidal ideation escalation (suicide is a known risk in untreated moderate-to-severe depression), and need for crisis intervention or inpatient stabilization. The cost of psychiatric hospitalization or emergency department utilization far exceeds the cost of outpatient psychotherapy. I request approval for 16 sessions of individual outpatient psychotherapy using CBT over the 4-month period. This request is medically necessary and clinically appropriate. Thank you for your prompt attention to this request. Please contact me if you require additional clinical information. Respectfully, [Clinician Name] [License Number] [Contact Information]

UTILIZATION REVIEW CLINICAL SUMMARY Patient: [Name] | MID: [Member ID] | DOB: [Date] | Age: [Age] DIAGNOSES: F33.1 Major Depressive Disorder, Recurrent, Moderate F41.1 Generalized Anxiety Disorder SYMPTOM SEVERITY: PHQ-9 Score (intake): 17 (moderate-to-severe depression) GAD-7 Score (intake): 14 (moderate anxiety) FUNCTIONAL IMPAIRMENTS: Occupational: Inconsistent work attendance, reduced productivity, difficulty managing responsibilities Sleep: 3–4 hours per night; sleep onset and maintenance insomnia Social: Withdrawal from relationships; reported isolation Self-care: Decreased engagement in valued activities CURRENT PHARMACOTHERAPY: Sertraline 100 mg daily (prescribed by PCP) — partial response achieved; residual moderate symptoms persist TREATMENT HISTORY: No prior psychotherapy documented. Patient currently managed by PCP for psychiatric medications only; no formal mental health treatment initiated. CLINICAL JUSTIFICATION FOR CONTINUED PSYCHOTHERAPY: Pharmacotherapy alone has produced partial response. Moderate depression with persistent functional impairment requires evidence-based psychotherapy (CBT) in combination with medication to achieve remission and prevent relapse. Standard treatment protocol is 12–20 sessions. PROGNOSIS WITH TREATMENT: With continued CBT + pharmacotherapy: Expected symptom reduction to mild or subclinical levels within 4 months; improved work attendance and occupational functioning; restored sleep and energy; reduced relapse risk. RISK WITHOUT CONTINUED TREATMENT: High risk of symptom escalation, job loss, social deterioration, increased suicidal ideation, and need for crisis intervention or hospitalization.